Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Company Overview

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Key Stats

• Today's Range: $26.04 to $27.45
• 50-Day Range: $21.89 to $30.18
• 52-Week Range: $14.52 to $31.26
• Volume: 103,480 shs
• Average Volume: 198,412 shs
• Market Capitalization: $87.31 billion
• P/E Ratio: 34.45
• Dividend Yield: 0.94%
• Price Target: N/A
• Consensus Rating: N/A

CHGCY Stock Analysis - Frequently Asked Questions

How have CHGCY shares performed this year?

Chugai Pharmaceutical's stock was trading at $21.97 at the beginning of 2025. Since then, CHGCY shares have increased by 20.8% and is now trading at $26.53.
View the best growth stocks for 2025 here.

How were Chugai Pharmaceutical's earnings last quarter?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) announced its quarterly earnings data on Thursday, April, 24th. The company reported $0.19 EPS for the quarter. The business earned $1.89 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a trailing twelve-month return on equity of 21.53%.

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/24/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drugs, proprietaries, & sundries
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CHGCY
• CIK: 1453934
• Web: www.chugai-pharm.co.jp
• Phone: (133) 281-6611
• Fax: N/A
• Employees: 7,604
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.81
• Trailing P/E Ratio: 34.45
• Forward P/E Ratio: 35.85
• P/E Growth: N/A
• Net Income: $2.56 billion
• Net Margins: 33.07%
• Pretax Margin: 46.39%
• Return on Equity: 21.53%
• Return on Assets: 18.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: $7.74 billion
• Price / Sales: 11.28
• Cash Flow: $0.91 per share
• Price / Cash Flow: 29.01
• Book Value: $3.81 per share
• Price / Book: 6.96

Miscellaneous

• Outstanding Shares: 3,291,028,000
• Free Float: N/A
• Market Cap: $87.31 billion
• Optionable: Not Optionable
• Beta: 0.76